Scenes from TTLC 2023

ILCN Editor Dr. Corey J. Langer Reflects on the ‘Fantastic Voyage’ From Nihilism to Hope in Thoracic Oncology

Specialists Debate the Merits of Lorlatinib as a Universal First-Line Treatment for ALK+ Patients

Study Explores First-Line Osimertinib for NSCLC Patients with Uncommon EGFR Mutations

New Texas Lung Cancer Conference Planned with Busy Clinicians in Mind

Mesothelioma Pioneer Delivers 2023 Heine H. Hansen Keynote Lecture

Thoracic Oncologists Divided Regarding Role of Neoadjuvant Chemoimmunotherapy

Investigator Shares Findings That Point to Possible Mechanism of SCLC Plasticity

Closing Keynote Highlights Progress, Challenges in Management of SCLC

Amivantamab Demonstrates Consistent Efficacy in CHRYSALIS Follow-up

Early Detection Researcher Shares Epidemiologic Evidence on Air Pollution, Lung Cancer

Analysis Shows Cancer Death Rates Must Decline Faster to Reach ‘Moonshot’ Goal